Pitolisant Shows Benefit for IH in Phase 3 Open-Label Trial, with Bruce Corser, MD

At SLEEP 2025, Bruce Corser, MD, discussed promising open-label data on pitolisant’s impact on idiopathic hypersomnia symptoms with HCPLive.

Read the full article here

Related Articles